RELAPSE
Clinical trials for RELAPSE explained in plain language.
Never miss a new study
Get alerted when new RELAPSE trials appear
Sign up with your email to follow new studies for RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat breast cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for triple negative breast cancer that has come back or not responded to other therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to che…
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 16, 2026 22:32 UTC
-
New cocktail aims to tame returning bone marrow cancer
Disease control Recruiting nowThis study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…
Matched conditions: RELAPSE
Phase: PHASE2 • Sponsor: Andrew Yee, MD • Aim: Disease control
Last updated May 16, 2026 22:32 UTC
-
Engineered immune cells take on tough pancreatic cancer
Disease control Recruiting nowThis study tests a new gene therapy for people with pancreatic cancer that has returned after standard treatment. The therapy uses the patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, and includes a safety switch to control side effects. The …
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug duo takes on tough lymphoma
Disease control Recruiting nowThis study tests whether combining two drugs, epcoritamab and loncastuximab tesirine, can safely shrink or eliminate lymphoma in people whose cancer has returned or stopped responding to treatment. About 26 adults with relapsed or refractory large B-cell lymphoma will receive the…
Matched conditions: RELAPSE
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Engineered immune cells take aim at Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis study tests a new treatment for Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein called CD30. About 31 participants will receive…
Matched conditions: RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Engineered immune cells take on recurrent head and neck cancer
Disease control Recruiting nowThis study tests a new treatment called iC9.CAR-CSPG4 T cells for people with head and neck cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals ar…
Matched conditions: RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Talking your way to sobriety: new study tests Post-Detox support
Symptom relief Recruiting nowThis study looks at whether having regular motivational conversations after leaving the hospital can help people with alcohol use disorder stay away from alcohol for a full year. About 104 adults who have completed alcohol withdrawal in the hospital will take part. Half will get …
Matched conditions: RELAPSE
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated May 16, 2026 22:30 UTC